This program will include a discussion of investigational agents not approved by the FDA for use in the United States IBD Background Evolving Treatment Landscape in IBD Limitations of Current IBD Therapies ID: 674313
Download Presentation The PPT/PDF document "Current and Emerging Treatments for IBD" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Current and Emerging Treatments for IBDSlide2Slide3
This program will include a discussion of
investigational agents not approved by the FDA for use in the United States. Slide4
IBD BackgroundSlide5
Evolving Treatment Landscape in IBDSlide6
Limitations of Current IBD TherapiesSlide7
Investigational Therapies: MOAsSlide8
Anti-Integrin TherapiesSlide9
Selective Adhesion Molecule InhibitorsSlide10
Etrolizumab in Moderate to Severe UC
Phase 2 StudySlide11
Etrolizumab in Moderate to Severe UC
Phase 2 Study ResultsSlide12
Abrilumab in Moderate to Severe UC
Phase 2b StudySlide13
Abrilumab in Moderate to Severe UC
Phase 2b Study ResultsSlide14
PF-00547659 Anti-MAdCAM-1 Antibody TURANDOT StudySlide15
S1P Receptor ModulatorsSlide16
S1P Receptor Modulators (cont)Slide17
Ozanimod in Moderate to Severe UC TOUCHSTONE StudySlide18
TOUCHSTONE Efficacy ResultsSlide19
Emerging Anti-Interleukin mAbs in IBDSlide20
Ustekinumab for IBDSlide21
Risankizumab in Moderate to Severe CD
Phase 2 StudySlide22
Risankizumab in Moderate to Severe CD
Phase 2 Study ResultsSlide23
Brazikumab in Moderate to Severe CD
Phase 2a StudySlide24
Mirikizumab in IBDSlide25
JAK InhibitorsSlide26
OCTAVE Trials: Tofacitinib in UCSlide27
OCTAVE 1 and 2 Efficacy ResultsSlide28
OCTAVE Sustain Efficacy ResultsSlide29
OCTAVE: Efficacy by Prior TNF Inhibitor ExposureSlide30
OCTAVE: Adverse EventsSlide31
Filgotinib in Moderate to Severe CD
FITZROY StudySlide32
Filgotinib in Moderate to Severe CD
FITZROY Study ResultsSlide33
Upadacitinib in Moderate to Severe CD
Celest StudySlide34
Upadacitinib in Moderate to Severe CD
Celest Study ResultsSlide35
Other Emerging Therapies
RifaximinSlide36
Other Emerging Therapies in IBDSlide37
Possibilities for Future Treatment in IBDSlide38
AbbreviationsSlide39
Abbreviations (cont)